Top Markets
Coin of the day
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
Rangering i aksjer #39496
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Aksjekurs
$0.1174299
Sist synkronisert: 2026-08-13
Markedsverdi
$467.84K
Endring (1 dag)
-8.57%
Endring (1 år)
1.38%
Land
CA
Handel Vaxil Bio Ltd. (VXL)

Kategori

P/S-forhold for Vaxil Bio Ltd. (VXL)
P/S-forhold per 2026 TTM: 0
Ifølge Vaxil Bio Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Vaxil Bio Ltd. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE